Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Infectious diseases
Sessions
Wednesday, 23 November
12:20
UNODC-WHO lunch-time session
Designing focused, tailored and prioritized HIV and viral hepatitis interventions for people who use drugs
12:20
to
13:10
Insights zone 3 (I3)
Andrej Kastelic
13:20
Prevention and control of infectious diseases among people who inject drugs: New evidence within the updated guidance from the ECDC and the EMCDDA
13:20
to
14:50
Networking zone 3 (N3)
Janelle Sandberg,
Thomas Seyler
16:50
Hepatitis C prevention and treatment among people who inject drugs: Global progress and future requirements
16:50
to
18:20
Knowledge market 3 (K3)
Jason Grebely,
Judy Chang
Thursday, 24 November
10:50
How can we improve global coverage of interventions to reduce drug-related harms?
10:50
to
12:20
Main stage
Annette Verster,
Matthew Hickman
13:20
Hepatitis C testing and treatment
13:20
to
14:50
Knowledge market 3 (K3)
Julie Bruneau,
Jason Grebely
15:00
Models to improve the health of people who inject drugs
15:00
to
16:30
Knowledge market 3 (K3)
Jonas Demant,
Rose Schmidt
Prevention, testing and treatment of Hepatitis C and other infections
15:00
to
16:30
Networking zone 4 (N4)
Sarah Larney
18:30
On the path towards elimination of hepatitis C – Models of care to reach people who inject drugs for testing and treatment
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Friday, 25 November
13:20
Barriers in the implementation of harm reduction interventions in European prisons. From evidence to practice
13:20
to
14:50
Main stage
Linda Montanari,
Liesbeth Vandam
Presentations
Oral presentation
Simplified HCV management algorithm for methadone clinics: a pilot study in Ukraine
Knowledge market 3 (K3)
Kostyantyn Dumchev
Short communication
Integrating hepatitis C treatment in methadone clinic in Ukraine: perspectives of participants and providers.
Networking zone 4 (N4)
Tetiana Kiriazova
Oral presentation
Progress towards elimination of hepatitis C among people who inject drugs in Norway
Knowledge market 4 (K4)
Knut Boe Kielland
Wednesday, 23 November
10:50
Oral presentation
1. Global epidemiology of injecting drug use, HIV/HCV among people who inject drugs, and coverage of interventions to reduce drug-related harms
10:50
to
12:20
Main stage
Louisa Degenhardt
Oral presentation
2. Successful models for implementation of harm reduction programmes
10:50
to
12:20
Main stage
Monica Ciupagea
Oral presentation
3. How can we improve data and mobilise funding for harm reduction support globally?
10:50
to
12:20
Main stage
Keith Sabin
Oral presentation
4. Community advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms
10:50
to
12:20
Main stage
Judy Chang
12:30
Oral presentation
1. Community perspective on access to harm reduction
12:30
to
13:10
Insights zone 3 (I3)
Judy Chang
Oral presentation
2. Documenting Egypt’s adoption and upcoming rollout of OAT
12:30
to
13:10
Insights zone 3 (I3)
Raghda Algamil
Oral presentation
3. Introducing the WHO Consolidated guidelines for key populations
12:30
to
13:10
Insights zone 3 (I3)
Annette Verster
Oral presentation
4. Introducing the UNODC-WHO OAT Operational tool and training package
12:30
to
13:10
Insights zone 3 (I3)
Monica Ciupagea
13:20
Oral presentation
1. Overview of the updated ECDC/EMCDDA guidance on the prevention and control of infectious diseases among people who inject drugs
13:20
to
14:50
Networking zone 3 (N3)
Anne Bergenstrom,
Janelle Sandberg
Oral presentation
2. Effectiveness of drug treatment, needle and syringe programmes and drug consumption rooms in the prevention of blood-borne viruses among people who inject drugs – updated evidence from reviews of empirical and mathematical modelling studies
13:20
to
14:50
Networking zone 3 (N3)
Matthew Hickman
Oral presentation
3. Enhancing the HCV care cascade among people who inject drugs: a systematic review and considerations from an expert panel
13:20
to
14:50
Networking zone 3 (N3)
Ilonka Horváth
Discussion
Perspectives from government and civil society member(s) of the ECDC and EMCDDA expert panel on the key areas of intervention
13:20
to
14:50
Networking zone 3 (N3)
Janelle Sandberg,
Anne Bergenstrom,
Anna Tarján,
Mat Southwell,
Viktor Mravcik,
Annette Verster,
Slava Kushakov
16:50
Oral presentation
2. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study
16:50
to
18:20
Knowledge market 4 (K4)
Linda Wüsthoff
Oral presentation
Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge clusterrandomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
16:50
to
18:20
Knowledge market 4 (K4)
Havard Midgard
Oral presentation
1. Interventions to enhance prevention of hepatitis C and HIV infection
16:50
to
18:20
Knowledge market 3 (K3)
Julie Bruneau
Oral presentation
2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle
16:50
to
18:20
Knowledge market 3 (K3)
Matthew Hickman
Oral presentation
3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?
16:50
to
18:20
Knowledge market 3 (K3)
Jason Grebely
Oral presentation
4. Community-led initiatives to enhance prevention and treatment for hepatitis C
16:50
to
18:20
Knowledge market 3 (K3)
Judy Chang
Thursday, 24 November
13:20
Oral presentation
Non-uptake of treatment for hepatitis C in the antiviral era: A qualitative analysis
13:20
to
14:50
Knowledge market 3 (K3)
Suzanne Fraser
Oral presentation
A novel hepatitis C intervention in Denmark to test and treat people who inject drugs
13:20
to
14:50
Knowledge market 3 (K3)
Jonas Demant
Oral presentation
Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study
13:20
to
14:50
Knowledge market 3 (K3)
Anna Conway
15:00
Oral presentation
The social, material and temporal effects of extended-release buprenorphine depot treatment for opioid dependence: an Australian qualitative study
15:00
to
16:30
Knowledge market 3 (K3)
Kari Lancaster
Short communication
Real-world hepatitis C treatment outcomes among people who inject drugs at the Stockholm needle exchange program, Sweden
15:00
to
16:30
Networking zone 4 (N4)
Martin Kåberg
Short communication
Educations for safer injection in the Mobile Drug Consumption Room in Lisbon
15:00
to
16:30
Networking zone 4 (N4)
Ângela Leite
Short communication
Real time surveillance on the impact of restrictions on harm reduction services to improve responsiveness and reduce harms in unprecedented times
15:00
to
16:30
Networking zone 4 (N4)
Josie Smith
Short communication
Harm reduction services in the Netherlands: recent developments and challenges.
15:00
to
16:30
Networking zone 4 (N4)
Nadine G.M. van Gelder
Oral presentation
Serious non-fatal and fatal opioid overdose events in a cohort of hospital patients seen by an addiction consultation service: Secondary analysis of the NavSTAR trial.
15:00
to
16:30
Knowledge market 3 (K3)
Jan Gryczynski
Oral presentation
Screening, diagnosis and treatment of infectious diseases with at-risk populations: 20 years of data from a harm reduction program managed by Ares do Pinhal in Lisbon
15:00
to
16:30
Knowledge market 3 (K3)
Filipa Barata
Oral presentation
Peer-led community based infectious disease integrated testing and linkage to care in inclusion health populations in London, UK
15:00
to
16:30
Knowledge market 3 (K3)
Julian Surey
Short communication
Transactional sex as a pathway for rising sexually transmitted infections amidst the opioid epidemic in the United States
15:00
to
16:30
Networking zone 4 (N4)
Mance Buttram
Short communication
Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland
15:00
to
16:30
Networking zone 4 (N4)
Claudia Bernardini
Short communication
Individual and structural factors associated with recent hepatitis C testing in people who inject drugs: gender-based analyses of the Cosinus Cohort
15:00
to
16:30
Networking zone 4 (N4)
Ilhame Anwar
18:30
Oral presentation
2. Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Oral presentation
3. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study, and the Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
1. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program. And new models to reach those hard to reach; results from Point of Care testing and treatment in a nurse led and a peer led mobile clinic
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Friday, 25 November
13:20
Oral presentation
5. Harm reduction interventions and viral hepatitis elimination in prison: models of care and barriers for implementation
13:20
to
14:50
Main stage
Lara Tavoschi
Oral presentation
4. Impact, role, and prevalence of medication assisted treatment (MAT) for opioid users in European prisons
13:20
to
14:50
Main stage
Heino Stöver
Oral presentation
1. Provision of harm reduction interventions in European prisons: short overview of available services
13:20
to
14:50
Main stage
Linda Montanari
Oral presentation
2. Hepatitis C and HIV associated risk factors among people in prison in Latvia, Lithuania, Portugal, Spain: informing interventions to prevent communicable diseases in prison setting
13:20
to
14:50
Main stage
Laura Isajeva
Oral presentation
3. The international guidance on harm reduction interventions in prisons
13:20
to
14:50
Main stage
Ehab Salah
Discussion
Prison health in Europe
13:20
to
14:50
Main stage
Fadi Meroueh,
Filipa Alves da Costa